Market Overview

UPDATE: Bank Of America Reiterates On PTC Therapeutics On Positive Outlook


In a report published Monday, Bank of America analyst Tazeen Ahmad reiterated a Buy rating on PTC Therapeutics (NASDAQ: PTCT), but lowered the price target from $50.00 to $48.00.

In the report, Bank of America noted, “We rate PTCT shares Buy. We use what we view as conservative assumptions for our sales ramp estimates for the key pipeline product ataluren in both the DMD and CF indications. Our view of ataluren's favorable safety profile, focus on rare disease categories with undermet need, lack of near term competition and expected near-term EU launch provide allows us to arrive at an NPV for PTCT shares that is significantly above the stock's current valuation.”

PTC Therapeutics closed on Friday at $34.59.

Latest Ratings for PTCT

May 2019UpgradesNeutralBuy
Apr 2019Initiates Coverage OnOutperform
Nov 2018MaintainsOverweightOverweight

View More Analyst Ratings for PTCT
View the Latest Analyst Ratings

Posted-In: Bank of America Tazeen AhmadAnalyst Color Price Target Analyst Ratings


Related Articles (PTCT)

View Comments and Join the Discussion!

Latest Ratings

HTHTDaiwa CapitalDowngrades
GSKNew StreetUpgrades
JNJCredit SuisseMaintains158.0
TDGCredit SuisseMaintains584.0
SCHWDeutsche BankReiterates35.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

UPDATE: D.A. Davidson Reiterates On Chart Industries On Mixed Prospects

Longbow Research Upgrades Whirlpool To Buy